One of the most predominant mechanisms of resistance to endocrine therapy in ER+ breast cancer is the cross-talk between ER and growth factor receptor pathways, which facilitates a transition from ligand (E2)-dependent to ligand-independent ER activation, ultimately leading to a reprogrammed ER transcriptional activity. Here, ESR1 is linked to breast cancer.